Cypherpunk Technologies (CYPH) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cypherpunk Technologies (CYPH) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 274.7% versus a loss of 44.0%. Over five years, LRMR leads with a -77.7% price change compared with -91.1% for CYPH. Cypherpunk Technologies is the larger company by market cap ($302.8 million vs $280.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYPH | LRMR |
|---|---|---|
| Share price | $2.81 | $2.70 |
| Market cap | $302.82M | $280.48M |
| 1-day change | -7.87% | -1.82% |
| YTD return | +142.24% | -29.13% |
| 1-year return | +274.67% | -43.98% |
| 5-year return | -91.08% | -77.72% |
| P/E ratio (TTM) | 4.46 | — |
| EPS (TTM) | $0.63 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.19 | $6.42 |
| 52-week low | $0.393 | $2.61 |
| Distance from 52-week high | -32.94% | -57.94% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +74.38% | +433.33% |
| Average volume | 9.88M | 1.31M |
| Shares outstanding | 107.76M | 103.88M |
| Employees | 6 | 71 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYPH has outperformed LRMR by 318.7 percentage points over the past year.
- The two companies sit in different sectors: Cypherpunk Technologies in Health Care and Larimar Therapeutics in Healthcare.
About Cypherpunk Technologies
CYPH stock →Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Healthcare · Biotechnology · 71 employees
CYPH vs LRMR FAQ
Which is bigger, Cypherpunk Technologies or Larimar Therapeutics?
Cypherpunk Technologies (CYPH) is larger, with a market capitalization of $302.82M compared with $280.48M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, CYPH or LRMR?
CYPH returned +274.67% over the past 12 months, compared with -43.98% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Cypherpunk Technologies and Larimar Therapeutics in the same industry?
No. Cypherpunk Technologies is in the Health Care sector, while Larimar Therapeutics is in Healthcare.